Experienced in Non-Hodgkin Lymphoma

Dr. Matthew C. Foster

Internal Medicine
170 Manning Drive Cb 7305, 3rd Floor Physicians Office Building, 
Chapel Hill, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Non-Hodgkin Lymphoma
170 Manning Drive Cb 7305, 3rd Floor Physicians Office Building, 
Chapel Hill, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Matthew Foster is a primary care provider, practicing in Internal Medicine in Chapel Hill, North Carolina. Dr. Foster is rated as an Experienced provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Multicentric Castleman Disease (MCD), Castleman Disease, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 52 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles and participated in 3 clinical trials in the study of Non-Hodgkin Lymphoma.

Specialties
Internal Medicine
Licenses
Internal Medicine in NC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

170 Manning Drive Cb 7305, 3rd Floor Physicians Office Building, Chapel Hill, NC 27599

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Samalizumab, BI-836858, Daunorubicin, Cytarabine, Azacitidine, AG-221, Entospletinib, Decitabine, Pevonedistat, AG-120, Gilteritinib, AZD5153, Venetoclax, TP-0903, AZD5991
Study Phase: Phase 1/Phase 2
Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma
Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Biological
Study Drug: ATLCAR.CD30 cells
Study Phase: Phase 1/Phase 2
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Enrollment Status: Suspended
Publish Date: November 17, 2025
Intervention Type: Biological
Study Drugs: Blinatumomab, Inotuzumab
Study Phase: Phase 2
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
Administration of Autologous CAR-T Cells Targeting the CD19 Antigen and Containing the Inducible caspase9 Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Administration of Autologous CAR-T Cells Targeting the CD19 Antigen and Containing the Inducible caspase9 Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: October 27, 2025
Intervention Type: Drug, Biological
Study Drugs: Rimiducid, Cyclophosphamide, Fludarabine, CD19-Positive/iC9 CAR-T Cells
Study Phase: Phase 1/Phase 2
Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging
Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Procedure, Other, Drug
Study Drugs: Cytarabine, Fluorothymidine F-18
Study Phase: Phase 2
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Suspended
Publish Date: September 05, 2025
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CPI-613, Cytarabine, Mitoxantrone, Etoposide, Fludarabine, Filgrastim
Study Phase: Phase 3
LCCC 1111: An Open-Label Dose-Finding Study of Lenalidomide as Reinduction/ Consolidation Followed by Lenalidomide Maintenance Therapy for Adults ≥ 60 Years of Age With Acute Myeloid Leukemia (AML) in Partial or Complete Response Following Conventional Induction Therapy
LCCC 1111: An Open-Label Dose-Finding Study of Lenalidomide as Reinduction/ Consolidation Followed by Lenalidomide Maintenance Therapy for Adults ≥ 60 Years of Age With Acute Myeloid Leukemia (AML) in Partial or Complete Response Following Conventional Induction Therapy
Enrollment Status: Completed
Publish Date: January 27, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: February 12, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 11 Less Clinical Trials

52 Total Publications

A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.
Journal: Cancer research communications
Published: February 17, 2025
Similar Doctors
Advanced in Non-Hodgkin Lymphoma
Dr. Anil V. Tumkur
Internal Medicine
Advanced in Non-Hodgkin Lymphoma
Dr. Anil V. Tumkur
Internal Medicine

Tennessee Cancer Specialists

1301 Sunset Dr, Ste 3, 
Johnson City, TN 
 (32.1 miles away)
423-588-7130
Languages Spoken:
English
See accepted insurances
Offers Telehealth

. Dr. Tumkur is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Acute Mountain Sickness, and Anemia.

Mark A. Williams
Experienced in Non-Hodgkin Lymphoma
Dr. Mark A. Williams
Internal Medicine
Experienced in Non-Hodgkin Lymphoma
Dr. Mark A. Williams
Internal Medicine

Johnson City Internal Medicine

301 Med Tech Pkwy, Ste 240, 
Johnson City, TN 
 (32.3 miles away)
423-794-5520
Languages Spoken:
English
See accepted insurances
Offers Telehealth

. Dr. Williams is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Sitosterolemia, Undifferentiated Connective Tissue Disease (UCTD), High Cholesterol, and Psoriatic Arthritis.

Ryan W. Shao
Experienced in Non-Hodgkin Lymphoma
Dr. Ryan W. Shao
Internal Medicine
Experienced in Non-Hodgkin Lymphoma
Dr. Ryan W. Shao
Internal Medicine

Ballad Health Medical Associates Oncology & Hematology

1 Medical Park Blvd, 
Bristol, TN 
 (51.1 miles away)
423-844-1121
Languages Spoken:
English
See accepted insurances

. Dr. Shao is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Thrombocytopenia, Anal Cancer, Familial Colorectal Cancer, and Small Cell Lung Cancer (SCLC).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Foster's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 10 Advanced Conditions
View All 45 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile